Glenmark Pharmaceuticals Ltd. has launched its new product range, Glempa, in India. The range consists of Empagliflozin, a widely recognized SGLT2 inhibitor, in three forms: Glempa (Empagliflozin 10/25 mg), Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg), and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). These medications are designed to improve glycemic control in adults with type 2 diabetes (T2DM) and reduce cardiovascular outcomes in T2DM patients with cardiovascular risk.
Empagliflozin is a well-established treatment for heart failure, T2DM, and T2DM with cardiovascular disease, offering multiple benefits such as cardiovascular and renal safety. A clinical trial demonstrated a 14% reduction in major cardiovascular events, making Empagliflozin a significant advancement in T2DM patients with high CV risks.
Studies have shown that Empagliflozin and its combinations are effective in reducing blood sugar levels, weight loss, and fasting blood sugar. A study found that a combination of Empagliflozin and Metformin helped patients lower their blood sugar levels, lose weight, and reduce fasting blood sugar. Another study showed that Empagliflozin with Linagliptin helped patients lower their HbA1c, lose weight, and reduce fasting blood sugar, proving more effective than either medicine alone.
Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals Ltd., commented on the launch, stating that Glenmark is committed to providing innovative and accessible treatments for cardiometabolic care in India. The launch of the Glempa range reinforces this commitment by providing a comprehensive and affordable solution for healthcare professionals and patients to manage T2DM with established CVD more effectively.
The Glempa range is designed to cater to diverse patient needs by offering three treatment options that enhance treatment flexibility and effectiveness. The Glempa range is expected to empower healthcare professionals and patients to manage T2DM with CVD more effectively, providing a range of treatment options for improved patient care.